Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
BrainStorm Hoping For Advisory Committee After FDA Refuses To File BLA For Its ALS Cell Therapy
Nov 15 2022
•
By
Derrick Gingery
A confirmatory trial is one possibility that BrainStorm will discuss with the FDA following NurOwn's refuse-to-file letter. • Source: Shutterstock
More from Approval Standards
More from Pathways & Standards